The Filing Desk

Agios Pharmaceuticals vs IM Cannabis

Agios Pharmaceuticals AGIO · IM Cannabis IMCC · Pharmaceuticals

Agios Pharmaceuticals reported revenue of $54 million in fiscal 2025, and IM Cannabis C$55 million in fiscal 2025, in different currencies. Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and IM Cannabis' grew 1.3%. Agios Pharmaceuticals had an operating margin of -873.9%, against -21.2% at IM Cannabis. Free cash flow was −$377 million at Agios Pharmaceuticals and C$5 million at IM Cannabis.

Side by side

Agios PharmaceuticalsIM Cannabis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$54MC$55M
Revenue growth48.0%1.3%
Revenue growth a year, last 5 years—28.0%
Gross margin88.3%17.7%
Operating margin−873.9%−21.2%
Net margin−764.0%−20.7%
Free cash flow−$377MC$5M
Free cash flow margin−698.3%8.6%
Return on capital—−64.9%
Net debt to EBITDA——
Dividends and buybacks$0MC$0M
Change in diluted share count0.1%—
Last close$28.76$0.47
P/E at the last close——
Insider trades, last 12 monthssold $4.3 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
Agios PharmaceuticalsIM Cannabis
Operating margin
Percent of revenue
Agios PharmaceuticalsIM Cannabis
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Agios PharmaceuticalsIM Cannabis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and IM Cannabis pages.